ACOG (2002). "ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002." Obstet Gynecol 99(1): 159-67.
Bdolah Y, L. C., Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, Lim KH, Bdolah-Abram T, Epstein FH, Karumanchi SA. (2008). "Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?" Am J Obstet Gynecol. 198(4): 428.e1-6.
Bdolah Y, P. G., Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA. (2006).
"Circulating angiogenic proteins in trisomy 13." Am J Obstet Gynecol. 194(1): 239-45.
Bobst SM, D. M., Gilstrap LC 3rd, Xia Y, Kellems RE. (2005). "Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretio." Am J Hypertens. 18(3): 330-6.
Brown KE, A. S., Young NS. (1993). "Erythrocyte P antigen: cellular receptor for B19 parvovirus." Science.
262(5130): 114-7.
Brown KE, H. J., Gallinella G, Anderson SM, Lehman ED, McCarthy P, Young NS. (1994). "Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen)." N Engl J Med. 330(17):
1192-6.
Brown MA, L. M., de Swiet M, Van Assche A, Moutquin JM. (2001). "The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)." Hypertens Pregnancy. 20(1): IX-XIV.
Carmeliet P, M. L., Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. (2001). "Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions." Nat Med. 7(5): 575-83.
Castellucci M, K. G., Verdenelli F, Huppertz B, Kaufmann P. (2000). "Villous sprouting: fundamental mechanisms of human placental development." Hum Reprod Update. 6(5): 485-94.
Chaiworapongsa T, R. R., Espinoza J, Bujold E, Mee Kim Y, Gonçalves LF, Gomez R, Edwin S. (2004). "Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award." Am J Obstet Gynecol. 190(6): 1541-7;.
Chien PF, A. N., Gordon A, Owen P, Khan KS. (2000). "How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview." BJOG 107(2): 196-208.
Chung O, K. H., Stoll M, Unger T. (1998). "Physiological and pharmacological implications of AT1 versus AT2 receptors." Kidney Int Suppl. 67: 95-9.
Clark DE, S. S., He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. (1998). "A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation." Biol Reprod. 59(6): 1540-8.
Cossart YE, F. A., Cant B, Widdows D. (1975). "Parvovirus-like particles in human sera." Lancet. 1(7898): 72-3.
Crispi F, D. C., Llurba E, Martín-Gallán P, Cabero L, Gratacós E. (2006). "Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction." Am J Obstet Gynecol. 195(1): 201-7.
Cudmore M, A. S., Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A. (2007). "Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1." Circulation 115(13): 1789-97.
De Vivo A, B. G., Giordano D, Todarello G, Corrado F, D'anna R. (2008). "Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia." Acta Obstet Gynecol Scand. 87(8): 837-42.
Dechend R, G. P., Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Müller DN. (2005). "Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia." Hypertension. 45(4): 742-6.
Dechend R, H. V., Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC.
(2000). "AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor." Circulation. 101(20): 2382-7.
Dechend R, H. V., Wallukat G, Müller DN, Krause M, Dudenhausen J, Haller H, Luft FC. (2006). "Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia." J Soc Gynecol Investig. 13(2): 79-86.
Dechend R, V. C., Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC (2003 ). "AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase." Circulation 107(12): 1632-9.
Dembinski J, E.-H. A., Maar J, Schild R, Bartmann P. (2002). "Long term follow up of serostatus after maternofetal parvovirus B19 infection." Arch Dis Child. 88(3): 219-21.
Demir R, K. U., Cayli S, Huppertz B. (2006 ). "Sequential steps during vasculogenesis and angiogenesis in the very early human placenta." Placenta. 27(6-7): 535-9.
Demir R, K. U., Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, Huppertz B. (2004). "Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis." Placenta. 25(6): 560-72.
Dorsch S, L. G., Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, Modrow S. (2002). "The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity." J Virol. 76(4): 2014-8.
Dragun D, M. D., Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G.
(2005). "Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection." N Engl J Med 352(6): 558-69.
Duckitt K, H. D. (2005). "Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies." BMJ. 330(7491): 565.
Duley, L. (2009). "The global impact of pre-eclampsia and eclampsia." Semin Perinatol 33(3): 130-7.
Edi Vaisbuch, M. J. E. W., MD; Sonia S. Hassan, MD; Roberto Romero, MD; Juan Pedro Kusanovic, MD; and M.
Y. S. David B. Cotton, MD; S. Ananth Karumanchi, MD (2010). "Circulating angiogenic and antiangiogenic
factors in women with eclampsia." Am J Obstet Gynecol.
Egbor M, A. T., Morris N, Green CJ, Sibbons PD. (2006). "Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction." BJOG 113(5): 580-9.
Eremina V, S. M., Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. (2003).
"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases." J Clin Invest. 111(5): 707-16.
Esser S, W. K., Wolburg H, Breier G, Kurzchalia T, Risau W. (1998). "Vascular endothelial growth factor induces endothelial fenestrations in vitro." J Cell Biol. 140(4): 947-59.
Faden H, G. G. J., Anderson LJ. (1992). "Chronic parvovirus infection in a presumably immunologically healthy woman." Clin Infect Dis. 15(4): 595-7.
Fan MM, T. L., Shippam-Brett C, Zagrodney DB, Astell CR. (2001). "The small 11-kDa protein from B19 parvovirus binds growth factor receptor-binding protein 2 in vitro in a Src homology 3 domain/ligand-dependent manner." Virology. 291(2): 285-91.
Ferrara (2005). "The role of VEGF in the regulation of physiological and pathological angiogenesis." EXS. 94: 209-31.
Ferrara, N. (2009). "VEGF-A: a critical regulator of blood vessel growth." Eur Cytokine Netw 20(4): 158-63.
Ferri C, G. D., Sebastiani M, Panfilo S, Abatangelo G, Zakrzewska K, Azzi A. (2002 ). "Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients." Arthritis Rheum. 46(8): 2262-3.
Frickhofen N, A. J., Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, Cohen R, Halperin I, King L, Mintzer D, et al. (1990). "Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS." Ann Intern Med. 113(12): 926-33.
Fu ML, H. H., Schulze W, Wallukat G, Micke P, Eftekhari P, Sjögren KG, Hjalmarson A, Müller-Esterl W, Hoebeke J. (2000). "Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension." J Hyper-tens. 18(7): 945-53.
Fu Y, I. K., Munakata Y, Saitoh T, Kaku M, Sasaki T. (2002). "Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2." J Virol. 76(11): 5395-403.
Gasser S, O. S., Brown EJ, Raulet DH. (2005). "The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor." Nature. 446(7054): 1186-90.
Genbacev O, J. R., Damsky CH, Polliotti BM, Fisher SJ (1996). "Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia." J Clin Invest. 97(2): 540-50.
Girardi G, Y. D., Thurman JM, Holers VM, Salmon JE. (2006). "Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction." J Exp Med 203(9): 2165-75.
Haller H, O. T., Hauck U, Distler A, Philipp T. (1989). "Increased intracellular free calcium and sensitivity to angiotensin II in platelets of preeclamptic women." Am J Hypertens 2(4): 238-43.
Harlow FH, B. M. (2001). "The diversity of diagnoses of preeclampsia." Hypertens Pregnancy. 20(1): 57-67.
Hauth JC, E. M., Levine RJ, Esterlitz JR, Sibai B, Curet LB, Catalano PM, Morris CD. (2000). "Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group." Obstet Gynecol. 95(1): 24-8.
He H, V. V., Gu X, Venema RC, Marrero MB, Caldwell RB. (1999). "Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src." J Biol Chem. 274(35).
He Y, S. S., Day KA, Clark DE, Licence DR, Charnock-Jones DS. (1999). "Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity." Mol Endocrinol. 13(4): 537-45.
Heegaard ED, R. C., Christensen J. (2002). "Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen." J Med Virol. 67(3): 375-83.
Heinrich PC, B. I., Haan S, Hermanns HM, Müller-Newen G, Schaper F. (2003). "Principles of interleukin (IL)-6-type cytokine signalling and its regulation." Biochem J 374(Pt1): 1-20.
Hnat MD, S. B., Caritis S, Hauth J, Lindheimer MD, MacPherson C, VanDorsten JP, Landon M, Miodovnik M, Paul R, Meis P, Thurnau G, Dombrowski M; (2002). "Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas." Am J Obstet Gynecol. 186(3): 422-6.
Hogberg, U. (2005). "The World Health Report 2005: "make every mother and child count" - including Africans."
Scand J Public Health 33(6): 409-11.
Hsu TC, W. W., Chen MC, Tsay GJ. (2004). "Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells." Scand J Infect Dis. 36(8): 570-7.
Hubel CA, W. G., Wolf M, Herse F, Rajakumar A, Roberts JM, Markovic N, Thadhani R, Luft FC, Dechend R.
(2007). "Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia." Hypertension. 49(3): 612-7.
Irani RA, Z. Y., Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. (2010 ). "Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling." Hypertension. 55(5): 1246-53.
Jeyabalan A, P. R., Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. (2010). "Effect of smoking on circulating angiogenic factors in high risk pregnancies." PLoS One. 5(10): e13270.
Jordan JA, B. A. (2002 ). "Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody." Placenta. 23(7): 547-53.
Jordan JA, H. D., DeLoia JA. (2000). "Placental cellular immune response in women infected with human parvovirus B19 during pregnancy." Clin Diagn Lab Immunol 8(2): Clin Diagn Lab Immunol.
Lam C, L. K., Karumanchi SA (2005 ). "Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia." Hypertension. 46(5): 1077-85.
LaMarca B, P. M., Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr, Ryan MJ, Dechend R. (2009). "Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1." Hypertension. 54(4): 905-9.
LaMarca B, W. G., Llinas M, Herse F, Dechend R, Granger (2008). "Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats." Hypertension.
52(6): 1168-72.
Leaños-Miranda A, C.-G. I., Alvarez-Jiménez G, Isordia-Salas I, Rivera-Leaños R, Ulloa-Aguirre A. (2010).
"Stimulating autoantibodies against the angiotensin II type 1 receptor are not associated with preeclampsia in Mexican-Mestizo women." J Hypertens. 28(4): 834-41.
Lehmann HW, P. A., von Landenberg P, Küster RM, Modrow S. (2008). "Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid-antibodies." Clin Rheumatol 27(3): 333-8.
Levine RJ, L. C., Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. (2006). "Soluble endoglin and other circulating antiangiogenic factors in preeclampsia." N Engl J Med. 355(10): 992-1005.
Levine RJ, M. S., Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. (2004). "Circulating angiogenic factors and the risk of preeclampsia."
N Engl J Med 350(7): 672-83.
Li Z, Z. Y., Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. (2007). "Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia." Hypertension. 50(4):
686-92.
Lunardi C, T. E., Bason C, Dolcino M, Corrocher R, Puccetti A. (2008 ). "Human parvovirus B19 infection and autoimmunity." Autoimmun Re 8(2): 116-20.
Lunardi C, T. M., Borgato L, Nanni L, Millo R, De Sandre G, Severi AB, Puccetti A. (1998). "Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties." Eur J Immunol. 28(3): 936-48.
Lunardi C, T. M., Borgato L, Nanni L, Millo R, De Sandre G, Severi AB, Puccetti A. (1998 ). "Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties." Eur J Immunol. 28(3): 936-48.
Luttun A, T. M., Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P. (2002). "Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1." Nat Med. 8(8): 831-40.
Manaresi E, G. G., Zerbini M, Venturoli S, Gentilomi G, Musiani M. (1999). "IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay." J Med Virol 57(2): 174-8.
Masuda Y, S. A., Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N. (2001).
"Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis." Am J Pathol. 159(2): 599-608.
Matsuo K, K. S., Dinc M, Sun CC, Kimura T, Baschat AA. (2007). "Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature." Am J Perinatol. 24(4): 257-66.
Maynard SE, M. J., Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. (2003). "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia." J Clin Invest. 111(5): 649-58.
Mitchell (2002). "Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections?" J Med Virol 67(2): 267-74.
Modrow S, D. S. (2002). "Antibody responses in parvovirus B19 infected patients." Pathol Biol (Paris). 50(5): 326-31.
Moffatt S, T. N., Tada K, Nose M, Nakamura M, Muraoka O, Hirano T, Sugamura K. (1996). "A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression."
J Virol. 70(12): 8485-91.
Moore Simas TA, C. S., Solitro MJ, Frost SC, Meyer BA, Maynard SE. (2007). "Angiogenic factors for the prediction of preeclampsia in high-risk women." Am J Obstet Gynecol. 197(3): 244.e1-8.
Murphy SR, L. B., Cockrell K, Granger JP. (2010). "Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats." Hypertension. 55(2): 394-8.
Muzammil S, S. U., Gulati R, Bano I. (2005). "Serum tumor necrosis factor-alpha in pre eclampsia." Indian J Physi-ol PharmacPhysi-ol. 49(2): 236-40.
Mylonas I, G. S., Anton G, Jeschke U, Weissenbacher ER, Friese K. (2007 ). "Parvovirus B 19 infection during pregnancy." Z Geburtshilfe Neonatol. 211(2): 60-8.
Naides SJ, S. L., Foto F, Howard EJ. (1990). "Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience." Arthritis Rheum. 33(9): 1297-309.
Nevo O, S. N., Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. (2006 ). "Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1." Am J Physiol Regul Integr Comp Physiol. 291(4): 1085-93.
NHBPEP (2000). "Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy." Am J Obstet Gynecol 183(1): S1-S22.
Osterud, B. (1997). "Tissue factor: a complex biological role." Thromb Haemost 78(1): 755-8.
Ozawa K, A. J., Kajigaya S, Shimada T, Young N. (1988). "The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells." J Virol. 62(8): 2884-9.
Parrish MR, M. S., Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B. (2010). "The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy." Am J Hypertens 23(8): 911-6.
Peterlana D, P. A., Beri R, Ricci M, Simeoni S, Borgato L, Scilanga L, Cerù S, Corrocher R, Lunardi C. (2003).
"The presence of parvovirus B19 VP and NS1 genes in the synovium is not correlated with rheumatoid arthritis." J Rheumatol. 30(9): 1907-10.
Pfrepper KI, E. M., Motz M (2005 ). "Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection." J Vet Med B Infect Dis Vet Public Health. 52(7-8): 362-5.
Powers RW, R. J., Cooper KM, Gallaher MJ, Frank MP, Harger GF, Ness RB. (2005). "Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia." Am J Obstet Gynecol. 193(1): 185-91.
Raab U, B. K., Lowin T, Niller HH, Doyle S, Modrow S. (2002). "NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3." Virology.
293(1): 86-93.
Ray NB, N. D., Seftor EA, Khalkhali-Ellis Z, Naides SJ. (2001). "Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts." Arthritis Rheum. 44(7): 1582-6.
Red-Horse K, Z. Y., Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher SJ. (2004). "Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface." J Clin Invest.
114(6): 744-54.
Redman CW, S. G., Sargent IL. (1999). "Preeclampsia: an excessive maternal inflammatory response to pregnancy."
Am J Obstet Gynecol. 180(2 Pt1): 499-506.
Saftlas AF, L. R., Klebanoff MA, Martz KL, Ewell MG, Morris CD, Sibai BM. (2003). "Abortion, changed paternity, and risk of preeclampsia in nulliparous women." Am J Epidemiol. 157(12): 1108-14.
Salafia CM, P. J., Ghidini A, Lopèz-Zeno JA, Whittington SS. (1998). "Clinical correlations of patterns of placental pathology in preterm pre-eclampsia." Placenta. 19(1): 67-72.
Salahuddin S, L. Y., Vadnais M, Sachs BP, Karumanchi SA, Lim KH. (2007). "Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy." Am J Obstet Gynecol.
197(1): 28.e1-6.
Scheurlen W, R. K., Wachowski O, Hemauer A, Modrow S. (2001). "Chronic autoimmune thrombopenia/neutropenia in a boy with persistent parvovirus B19 infection." J Clin Virol. 20(3): 173-8.
Schjetlein R, A. M., Haugen G, Husby H, Sandset PM, Wisløff F. (1999). "Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia." Acta Obstet Gynecol Scand. 78(3): 191-7.
Schneider, S. (2011). "Risk groups and maternal-neonatal complications of preeclampsia--current results from the national German Perinatal Quality Registry." J Perinat Med 39(3): 257-65.
Sela S, I. A., Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. (2008). "A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-human-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia." Circ Res. 102(12): 1566-74.
Shade RO, B. M., Cotmore SF, Tattersall P, Astell CR. (1986). "Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis." J Virol. 58(3): 921-36.
Shan HY, R. S., Epstein FH, Stillman IE, Karumanchi SA, Williams ME. (2008). "Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis."
Am J Kidney Dis. 51(6): 1029-32.
Shenoy V, K. K., Kalluri R. (2010). "Pre-eclampsia: connecting angiogenic and metabolic pathways." Trends Endocrinol Metab. 21(9): 529-36.
Siddiqui AH, I. R., Blackwell SC, Ramin SM, Kellems RE, Xia Y. (2010 ). "Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity." Hypertension. 55(2):
386-93.
Smith GC, W. H. (2009). "The perinatal implications of angiogenic factors." Curr Opin Obstet Gynecol. 21(2): 111-6.
Stegbauer J, C. T. (2010). "New insights into angiotensin receptor actions: from blood pressure to aging." Curr Opin Nephrol Hypertens. .
Stepan H, F. R., Wessel N, Wallukat G, Schultheiss HP, Walther T (2006). "Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia." J Clin Endocrinol Metab 91(6): 2424-7.
Stepan H, U. A., Wessel N, Faber R. (2007). "Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion." Hypertension. 49(4): 818-24.
Stepan H, W. G., Schultheiss HP, Faber R, Walther T. (2007). "Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor?" J Reprod Immunol 73(2): 130-4.
Sugimoto H, H. Y., Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. (2003). "Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria." J Biol Chem. 278(15): 12605-8.
Suzuki H, O. A., Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. (2009). "Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice." Hypertension. 54(5): 1129-35.
Thadhani, R. (2011). "Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia."
Circulation 124(8): 940-50.
Thadhani R, M. W., Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. (2004). "First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia." J Clin Endocrinol Metab. 89(2): 770-5.
Thway TM, S. S., Day MC, Sanborn BM, Gilstrap LC 3rd, Xia Y, Kellems RE. (2004). "Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation." Circulation. 110(12): 1612-9.
Tschöpe C, B. C., Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kühl U, Kandolf R, Schultheiss HP. (2005). "High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction." Circulation. 111(7): 879-86.
Tzang BS, T. C., Tsay GJ, Wang M, Sun YS, Hsu TC (2009). "Anti-human parvovirus B19 nonstructural protein antibodies in patients with rheumatoid arthritis." Clin Chim Acta. 405(1-2): 76-82.
Verlohren S, G. A., Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H.
(2010 ). "An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia." Am J Obstet Gynecol. 202(2): 161.e1-161.e11.
Verlohren S, N. M., Hering L, Geusens N, Herse F, Tintu AN, Plagemann A, LeNoble F, Pijnenborg R, Muller DN, Luft FC, Dudenhausen JW, Gollasch M, Dechend R. (2008). "Uterine vascular function in a transgenic preeclampsia rat model." Hypertension. 51(2): 547-53.
Von Landenberg P, L. H., Knöll A, Dorsch S, Modrow S. (2003). "Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection." Arthritis Rheum. 48(7):
1939-47.
von Poblotzki A, H. A., Gigler A, Puchhammer-Stöckl E, Heinz FX, Pont J, Laczika K, Wolf H, Modrow S. (1995 ).
"Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis." J Infect Dis. 172(5): 1356-9.
Vuorela P, H. S., Hornig C, Alitalo K, Weich H, Halmesmäki E. (2000). "Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia." Obstet Gynecol. 95(3): 353-7.
Wallukat G, H. V., Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Duden-hausen JW, Haller H, Luft FC. (1999). "Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor." J Clin Invest. 103(7): 945-52.
Walther T, W. G., Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H. (2005). "Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature." Hypertension. 46(6):
1275-9.
Wegner CC, J. J. (2004 ). "Human parvovirus B19 VP2 empty capsids bind to human villous trophoblast cells in vitro via the globoside receptor." Infect Dis Obstet Gynecol. 12(2): 69-78.
Weigel-Kelley KA, Y. M., Srivastava A. (2003). "Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry." Blood. 102(12): 3927-33.
WHO (2005). "The World Health Report: Make Every Mother and Child count."
Wulff C, W. M., Kreienberg R, Fraser HM (2003 ). "Angiogenesis during primate placentation in health and disease." Reproduction. 126(5): 569-77.
Xia Y, W. H., Kellems RE (2002). "Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation." J Biol Chem. 277(27): 24601-8.
Yang JC, H. L., Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA.
(2003). "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer." N Engl J Med. 349(5): 427-34.
Yinon Y, K. J., Odutayo A, Moineddin R, Drewlo S, Lai V, Cherney DZ, Hladunewich MA. (2010). "Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk." Circulation 122(18): 1846-53.
Zakrzewska K, C. R., Tonello C, Panfilo S, Abatangelo G, Giuggioli D, Ferri C, Corcioli F, Azzi A. (2005). "Human parvovirus B19 experimental infection in human fibroblasts and endothelial cells cultures." Virus Res.
114(1-2): 1-5.
Zhang J, V. J., Sun W, Merialdi M, Abdel-Aleem H, Mathai M, Ali M, Yu KF, Zavaleta N, Purwar M, Nguyen TN, Campodonico L, Landoulsi S, Lindheimer M, Carroli G. (2007). "Blood pressure dynamics during pregnancy and spontaneous preterm birth." Am J Obstet Gynecol. 197(2): 162.e1-6.
Zhou CC, A. S., Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A, Kellems RE, Xia Y. (2008). "Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling." Hypertension. 51(4): 1010-9.
Zhou CC, A. S., Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y. (2007). "Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy." Circ Res. 100(1): 88-95.
Zhou Y, F. S., Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH (1997 ). "Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?" J Clin Invest. 99(9): 2139-51.
Zhou Y, G. O., Fisher SJ. (2003). "The human placenta remodels the uterus by using a combination of molecules that govern vasculogenesis or leukocyte extravasation." Ann N Y Acad Sci. 995: 73-83.